The Fear
The belief that testosterone causes or accelerates prostate cancer has been one of the most persistent fears surrounding TRT. The landmark TRAVERSE trial — the largest randomized, controlled TRT safety study ever conducted (5,246 men) — found no increased risk of prostate cancer with testosterone therapy. The old narrative has been disproven. That said, baseline PSA testing and ongoing monitoring remain smart clinical practice because TRT can affect PSA values, and screening catches problems early.
For decades, the relationship between testosterone and prostate cancer was summarized as "adding fuel to the fire." This belief originated from observations in the 1940s by Charles Huggins, who found that castration (removing testosterone) caused prostate tumors to regress. The inference — that more testosterone must therefore cause or accelerate prostate cancer — became medical dogma for over 60 years.
Modern evidence has systematically dismantled this belief. The reality is more nuanced: testosterone doesn't cause prostate cancer, but responsible clinicians still monitor the prostate because good medicine means tracking what we can measure.
What PSA Actually Measures
Prostate-Specific Antigen (PSA) is a protein produced by prostate cells. It's present in the blood of all men — it's not a "cancer marker" in the traditional sense. PSA is elevated by:
- Prostate cancer — yes, but this is only one of many causes
- Benign prostatic hyperplasia (BPH) — enlarged prostate, common with aging
- Prostatitis — prostate inflammation or infection
- Recent ejaculation — can temporarily elevate PSA
- Vigorous exercise — particularly cycling
- Testosterone therapy — TRT modestly increases PSA in many men
A rising PSA doesn't mean you have cancer. It means something is stimulating your prostate. Context matters enormously — which is why baseline testing before TRT is essential for interpreting any subsequent changes.
What TRAVERSE Proved
The TRAVERSE trial was specifically designed to answer the safety questions surrounding TRT, including prostate risk. Key prostate-related findings:
- No increased incidence of prostate cancer: The rate of prostate cancer was not significantly different between the testosterone and placebo groups over the trial period
- No increase in high-grade prostate cancer: Clinically significant (Gleason score ≥7) prostate cancers were not more common in treated men
- Modest PSA increases expected: Men on TRT did show small PSA elevations, consistent with normal prostate stimulation by androgens — but these did not translate into cancer risk
In response to this data, the FDA's February 2025 labeling update removed the unsupported prostate cancer warnings from testosterone product labels. For the full picture on TRT safety data, see our dedicated TRAVERSE trial article.
Why Baseline PSA Matters
Even though TRT doesn't cause prostate cancer, testing PSA before starting therapy is non-negotiable. Here's why:
- Establishing a reference point: TRT typically raises PSA by 0.5–1.0 ng/mL. If you don't know where you started, you can't interpret whether a subsequent PSA value represents normal TRT-related stimulation or something that needs investigation.
- Screening for occult disease: In rare cases, a man may have undiagnosed prostate cancer before starting TRT. While testosterone doesn't cause the cancer, it can theoretically stimulate existing hormone-sensitive tumors. A baseline screen catches this before therapy begins.
- Velocity tracking: PSA velocity (how quickly PSA rises over time) is a more clinically useful metric than a single snapshot. Rapid increases (>0.75 ng/mL per year) warrant urological evaluation regardless of TRT status.
Monitoring on TRT
Standard monitoring protocols for PSA during TRT:
| Timepoint | PSA Action |
|---|---|
| Before starting TRT | Baseline PSA (required) |
| 3–6 months after starting | Recheck PSA |
| 12 months | Annual PSA |
| Ongoing | Annual PSA (men over 40) or per provider guidance |
Red flags that warrant urological referral:
- PSA above 4.0 ng/mL at any point (standard screening threshold)
- PSA velocity exceeding 0.75 ng/mL per year
- PSA doubling from baseline within 12 months
- New urinary symptoms (difficulty starting, weak stream, frequency)
The Bottom Line on Prostate Safety
Prostate fear should not prevent men with genuine testosterone deficiency from getting treatment. The evidence is clear: TRT does not cause prostate cancer, and the TRAVERSE trial — conducted in a high-risk population specifically chosen to test this question — confirmed this definitively.
What prostate monitoring on TRT represents is responsible medicine, not a warning sign. It's the same principle as checking hematocrit or estradiol — you monitor because you're a diligent patient, not because you're expecting disaster.
If you're over 40, have a family history of prostate cancer, or have any baseline urinary symptoms, discuss prostate monitoring with your provider before starting TRT. See our bloodwork guide for the full panel you need.